The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...
GlobalData on MSN6d
New CEOs to join Merck KGaA’s executive boardE. Merck KG board of partners has announced the appointment of new CEOs to Merck KGaA’s executive board, aiding its ongoing ...
If and when approved by shareholders and regulators, the combined company will retain Pfizer's global operational headquarters ... will create a leading global pharmaceutical company with the ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva Pharmaceutical ...
Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...
In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback